Kintor Pharmaceutical Limited 2025 Annual Report: Major Highlights and Shareholder Updates

Executive Summary

Kintor Pharmaceutical Limited’s 2025 Annual Report contains several significant developments, risk factors, and strategic initiatives that are highly relevant to shareholders and may impact share prices. The company, listed under Chapter 18A for biotechnology firms, remains pre-revenue from drug commercialization and faces ongoing financial challenges and uncertainties. The report includes a disclaimer of opinion from auditors regarding the company’s ability to continue as a going concern, which is a critical price-sensitive issue. The company has also provided detailed mitigation plans, recent financing activities, and updates on its clinical pipeline.

Key Financial Highlights

• Losses and Liquidity: Kintor incurred a loss and total comprehensive loss of RMB200.1 million for the year ended 31 December 2025. Net cash outflow from operating activities was RMB169.7 million. As of year-end, current liabilities exceeded current assets by RMB72.33 million, which includes borrowings of RMB85 million and trade and other payables of RMB41.97 million, with RMB17.94 million overdue for more than twelve months.
• Financial Ratios: The current ratio sharply declined from 103% in 2024 to 43.3% in 2025, signaling increased liquidity stress. The gearing ratio was 21.6%, reflecting the emergence of net debt, whereas in 2024 cash exceeded borrowings.
• Auditor’s Disclaimer of Opinion: PricewaterhouseCoopers issued a disclaimer of opinion regarding going concern due to multiple material uncertainties. These include the need for successful share placement, refinancing, commercialization of lead drug candidate KX-826, supplier payment deferrals, and improvement in operating cash flow.

Mitigation Plans and Capital Raising

• Plans and Measures: Kintor has outlined several plans to address liquidity concerns:
  • Obtained RMB43 million financing after year-end for operations and repayment of borrowings.
  • Plans for additional equity financing and increased bank credit quotas.
  • Active negotiations with banks for refinancing and with suppliers to defer overdue payments.
  • Enhanced sales of cosmetic products to boost gross margin and operating cash flow.
  • Potential disposal of certain financial assets to improve liquidity.
• Recent Fundraising:
  • Top-up Placing 2025: Issued 20,673,000 shares at HK\$2.08 (net price HK\$1.95), raising HK\$40.3 million, fully allocated to working capital for administrative and selling/marketing expenses.
  • Share Subscription 2025: Issued 30,487,500 shares at HK\$1.64 (net price HK\$1.63) to Hua Yuan International Limited, raising HK\$49.8 million. 40% allocated to Phase III clinical trial of KX-826 for androgenetic alopecia (AGA), 60% for selling/marketing expenses. Remaining balance is expected to be used by end of 2026.

Material Risks and Uncertainties

• Going Concern: The company’s ability to continue as a going concern is dependent on the successful implementation of its mitigation plans. Failure will require significant write-downs of assets and reclassification of liabilities, which could substantially impact shareholder value.
• Biotech Industry Risks: As a pre-revenue drug biopharmaceutical company, Kintor’s future depends on successful completion and commercialization of clinical trials, particularly for KX-826 and GT20029. Regulatory approval is not guaranteed, and commercialization involves uncertain outcomes and lengthy processes.
• Financial Risks: Exposure to market risks (forex, interest rate), credit risk, and liquidity risk is high due to reliance on external financing and operating losses.

Corporate Governance and Shareholder Rights

• Corporate Governance: The Board and Audit Committee have reviewed the Auditor’s disclaimer and mitigation plans, and agree with management’s position. The company continues to emphasize transparency, risk management, and compliance with Hong Kong regulations.
• Dividend Policy: No final dividend was recommended for 2025. The company has nil distributable reserves under IFRS as at year-end, and future dividends depend on profit, reserves, and PRC laws on subsidiary distributions.
• Shareholder Communication: Shareholders are encouraged to engage via AGM, email, and company website. Extraordinary general meetings may be convened by shareholders holding at least 10% of paid-up capital.
• Share Capital Movements: As at 31 December 2025, issued share capital increased to 498,660,100 shares following the above fundraising activities.
• Key Shareholders: KT International Investment Limited holds 10.3%, Suzhou Industrial Park-related entities collectively hold 9.85%, and Hua Yuan International Limited holds 6.11%.

Pipeline and R&D Update

• KX-826: Phase III clinical trials for the treatment of AGA are ongoing and remain a crucial milestone for the company’s commercial prospects and share price.
• Employee Incentive Scheme: Share-based compensation and awards continue to form part of employee remuneration, with vesting schedules and fair value disclosures.

Other Notable Points

• Audit Committee Review: After detailed assessment, the Audit Committee concurs with management’s mitigation strategies but acknowledges that uncertainties remain.
• No Material Breach/Compliance: The company reports full compliance with relevant laws and regulations; no material incidents or complaints affecting operations.
• Future Plans: Apart from disclosed plans, the company has no material investments or capital asset plans pending.

Conclusion

The 2025 Annual Report of Kintor Pharmaceutical Limited contains crucial, price-sensitive information. The auditor’s disclaimer regarding going concern, the company’s mitigation strategies, and the outcome of clinical trials for KX-826 are central to the future of the company and its share value. Investors should closely monitor these developments, as successful fundraising or clinical milestones could positively impact share price, while failure to resolve liquidity issues or achieve regulatory approval could result in significant downside risk.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The information is based on Kintor Pharmaceutical Limited’s 2025 Annual Report and is subject to change. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions.

View KINTOR PHARMA-B Historical chart here